ZURICH, Switzerland — September 10, 2025 — Leads & Copy — CUTISS, a TechBio company focused on tissue therapeutics and regenerative medicine, has completed a CHF 56M Series C funding round with existing and new investors, bringing total funds raised to over CHF 125M. The funding will support the Phase 3 trial and commercialization preparation for denovoSkin™, a bio-engineered, personalized skin graft. It will also advance the automation platform for tissue bioengineering and enable the market launch of VitiCell®.
CUTISS has also signed an agreement with Rode Kruis Ziekenhuis (RKZ) to establish a basis for a future CUTISS production center in The Netherlands, pending denovoSkin™ approval. RKZ is an EU clinical trials center participating in denovoSkin™ trials.
CUTISS CEO and co-founder Dr. Daniela Marino expressed gratitude for investor confidence and welcomed the partnership with RKZ, anticipating a revolution in the skin surgery market. Nadine Vieleers, CEO of Rode Kruis Ziekenhuis / Burn Center Beverwijk, affirmed their commitment to supporting CUTISS and the development of denovoSkin™ to bring revolutionary skin tissue therapy to patients.
Contact: Toomas Kull, kull@cpc-pr.com, +41 767 480 174
Source: CUTISS
